BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24492834)

  • 21. Contralateral risk-reducing mastectomy in young women.
    Merck B
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():29-32. PubMed ID: 20711671
    [No Abstract]   [Full Text] [Related]  

  • 22. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
    Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; BalmaƱa J; Meirovitz A; Domchek SM
    Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
    Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.
    Rosenberg SM; Tracy MS; Meyer ME; Sepucha K; Gelber S; Hirshfield-Bartek J; Troyan S; Morrow M; Schapira L; Come SE; Winer EP; Partridge AH
    Ann Intern Med; 2013 Sep; 159(6):373-81. PubMed ID: 24042365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
    J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
    Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
    JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving perspectives in contralateral breast cancer.
    Dawson LA; Chow E; Goss PE
    Eur J Cancer; 1998 Dec; 34(13):2000-9. PubMed ID: 10070301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
    J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
    Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
    Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
    Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation.
    Narod SA; Butler R; Bobrowski D; Akbari MR; Curling D; Lunn J; Ho C; Panahi S; Llacuachaqui M; Donenberg T; Hurley J
    Mol Genet Genomic Med; 2018 Mar; 6(2):301-304. PubMed ID: 29266833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic bilateral mastectomy and contralateral prophylactic mastectomy.
    Chagpar AB
    Surg Oncol Clin N Am; 2014 Jul; 23(3):423-30. PubMed ID: 24882342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-to-Benefit Relationship of Contralateral Prophylactic Mastectomy: The Argument for Bilateral Mastectomies with Immediate Reconstruction.
    Alba B; Schultz BD; Cohen D; Qin AL; Chan W; Tanna N
    Plast Reconstr Surg; 2019 Jul; 144(1):1-9. PubMed ID: 31246789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
    Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
    Clin Breast Cancer; 2018 Apr; 18(2):e205-e218. PubMed ID: 29050918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
    Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic mastectomy for the prevention of breast cancer.
    Lostumbo L; Carbine N; Wallace J; Ezzo J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
    Yi M; Hunt KK; Arun BK; Bedrosian I; Barrera AG; Do KA; Kuerer HM; Babiera GV; Mittendorf EA; Ready K; Litton J; Meric-Bernstam F
    Cancer Prev Res (Phila); 2010 Aug; 3(8):1026-34. PubMed ID: 20647335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.